Pharma Q1 Results Preview - India Formulations To Post Strong Growth On Low Base: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We expect pharmaceuticals companies under our coverage to report revenue/Ebitda/profit before tax growth of 13%/21%/31% YoY in Q1 FY22, while diagnostic companies to report 58%/139%/203% YoY growth.
The growth is largely led by lower base and volume up-tick on the back of increased domestic demand.
In base, sales were impacted due to logistic issues and lack of regulatory guidelines/infrastructure on RT/PCR tests.
Unlike strict lockdown restriction in last year, there are better recoveries and lesser logistic issues of global economies in Q1 FY22.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.